trending Market Intelligence /marketintelligence/en/news-insights/trending/fl2fhehxwbra5e_uookzya2 content esgSubNav
In This List

Hisamitsu's skin patch for Parkinson's treatment succeeds in phase 3 study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Hisamitsu's skin patch for Parkinson's treatment succeeds in phase 3 study

Hisamitsu Pharmaceutical Co. Inc. said the phase 3 study in Japan of its skin patch for Parkinson's disease met its main goal.

The product, called HP-3000, or ropinirole hydrochloride, was compared to placebo and with an oral drug in patients with Parkinson's disease who use levodopa.

The drug showed statistically significant results in effectiveness, compared to placebo, and worked just as well as the oral drug.

The Japanese drugmaker said the drug did not show any side effects that would cause any major concerns.

Parkinson's disease affects the nervous system and is characterized by tremors, impaired movements, problems with recognition and mood disorders.

Hisamitsu intends to apply for manufacturing and marketing approval within the year.